摘要目的评估血清甲胎蛋白(AFP)升高而MR检查阴性者确诊肝细胞癌(HCC)的时间间隔。材料与方法本研究为回顾性研究,经伦理委员会批准并符合HIPAA法案,免除病人的知情同意。研究共纳入2002—2011年间血AFP水平升高(>300 ng/mL或300μg/L),MR肝脏检查结果阴性的病人17例。回顾病人MR报告、病理报告和病历记录追踪病人最终结局,即是否最终确诊为HCC及血清AFP水平变化情况。分析初始和随访MRI评价肝脏是否存在结节及结节大小。AFP值差别采用变异值的重复检验分析。结果随访平均时间138 d(41~247 d)后,确诊为肝细胞癌10例(59%)(13 Abstract Objective To evaluate the time interval between diagnosis of hepatocellular carcinoma (HCC) and elevated serum alpha-fetoprotein (AFP). Materials and Methods This study, a retrospective study, was approved by the Ethics Committee and complied with the HIPAA Act to dispense with patients’ informed consent. The study included 17 patients with elevated blood AFP levels (> 300 ng / mL or 300 μg / L) between 2002 and 2011 and negative MR liver results. Review patient MR reports, pathology reports and medical records to track the patient’s final outcome, ie whether the final diagnosis of HCC and serum AFP level changes. Initial and follow-up MRIs were analyzed for the presence or absence of nodules and nodules in the liver. AFP value differences using repeated testing of variance analysis. Results After a mean follow-up of 138 days (41-247 days), 10 cases (59%) of hepatocellular carcinoma were diagnosed